Galleri Multi-Cancer Test Significantly Boosts Early Cancer Detection

The PATHFINDER 2 study results, presented at ASCO 2026, indicate that GRAIL's Galleri multi-cancer early detection test substantially increased cancer detection. The test demonstrated robust performance and a favorable safety profile in over 35,000 participants. Notably, more than half of the newly detected cancers were in early stages, and many lacked existing screening recommendations, highlighting the test's potential impact.